A bill to amend the Public Health Service Act with respect to the drug discount program, and for other purposes.
Summary
S5244, a bill to amend the Public Health Service Act regarding the drug discount program (340B), was introduced on August 5, 2026, and referred to the Senate HELP Committee. At this early stage, no specific market impact can be determined; the bill lacks detailed text and has not moved beyond committee referral.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S5244 is in the earliest legislative stage with no actionable details on 340B program changes.
- 2.Bipartisan cosponsorship suggests potential for progress, but no market-moving information is available yet.
- 3.Investors should wait for committee markup or released bill text before assessing impact on pharmaceutical or hospital stocks.
Market Implications
There are no current market implications from S5244. The bill is at the referral stage, and without text or committee action, it does not affect any company's revenue or competitive position. Investors in healthcare sectors (pharmaceuticals, hospitals, PBMs) should monitor the HELP Committee for future developments.
Full Analysis
Senator Moran (R-KS) introduced S5244 on August 5, 2026, with bipartisan cosponsorship from Senators Baldwin (D-WI), Capito (R-WV), Kaine (D-VA), Boozman (R-AR), and Hickenlooper (D-CO). The bill aims to amend the Public Health Service Act with respect to the drug discount program, commonly known as 340B. The 340B program requires drug manufacturers to provide outpatient drugs at discounted prices to covered entities (hospitals serving low-income populations). The bill's specific provisions are not publicly available at this stage. It has been read twice and referred to the Committee on Health, Education, Labor, and Pensions (HELP). No further legislative actions have occurred. As an early-stage authorization bill with no explicit funding amount, it does not directly allocate money. The legislative path includes committee hearings, markup, floor consideration, and potential House passage. Given the early stage and lack of detail, no concrete market impact can be assessed. Investors should monitor committee activity for amendments or a full bill text that would clarify whether the program is expanded, restricted, or otherwise modified.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.0B Department of Health and Human Services Grant
DEPARTMENT OF SOCIAL SERVICES CONNECTICUT: $6.9B Department of Health and Human Services Grant
STATE OF COLORADO - DEPT OF HEALTH CARE POLICY & FINANCING: $9.2B Department of Health and Human Services Grant
LOUSIANA DEPARTMENT OF HEALTH: $16.7B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $13.9B Department of Health and Human Services Grant
OKLAHOMA HEALTH CARE AUTHORITY: $8.1B Department of Health and Human Services Grant
ILLINOIS DEPARTMENT OF HEALTHCARE & FAMILY SERVICES: $23.4B Department of Health and Human Services Grant
NEBRASKA DEPARTMENT OF HEALTH & HUMAN SERVICES: $3.9B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →